Broncho-Vaxom

Phase 3Small molecule

OOM Pharma SA

Broncho-Vaxom is one of 12 small molecule programs targeting Wheezing. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

WheezingRecruiting

Idiopathic Nephrotic SyndromeActive, not recruiting

WheezingPhase 3

Recruiting

Idiopathic Nephrotic SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Wheezing

#DrugCompanyPhaseTrials

Flovent

PParatek Pharmaceuticals Inc

Approved

1 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 3

Spiriva

Boehringer Ingelheim

Approved

1 4

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

1 5

Broncho-Vaxom

OOM Pharma SA

Phase 3

2 6

Prednisolone Sodium Phosphate

UUniversity of Oulu

Phase 3

1 7

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

—8

Resveratrol

NNational Cancer Institute (NCI)

Preclinical

1 9

Inhaled Albuterol

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Wheezing

NCT05063149

Clinical

Trials by Indication[1]

Wheezing2 trials

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

Completed·UUniversity of Arizona·Phase 2·NCT02148796·822 enrolled

Protecting Late-moderate Preterm Infants From Respiratory Tract Infections and Wheeze in Their First Years of Life by Using Bacterial Lysates.

Recruiting·FFranciscus Gasthuis·Phase 3·NCT05063149·500 enrolled

Atopic Dermatitis1 trial

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Completed·VVifor Pharma·Phase 3·NCT03047954·179 enrolled

Asthma1 trial

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT04129931·395 enrolled

Idiopathic Nephrotic Syndrome1 trial

Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

Unknown status·FFang Deng·N/A·NCT05044169·83 enrolled

COVID-191 trial

Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

Completed·TThe University of Queensland·Phase 3·NCT04496245·59 enrolled

1 more indication

Immunomodulation1 trial

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

Terminated·OOM Pharma SA·Phase 2·NCT05222516·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Broncho-Vaxom. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Broncho-Vaxom compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Broncho-Vaxom. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OM Pharma SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOM Pharma SA

Broncho-Vaxom

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Wheezing2 trials

Atopic Dermatitis1 trial

Asthma1 trial

Idiopathic Nephrotic Syndrome1 trial

COVID-191 trial

Immunomodulation1 trial

References

Drug Info

Quick Facts

Related News